New study shows UroAmp can detect bladder cancer not found by cystoscopy or urine cytology
Noninvasive Genomic Urine Test Demonstrates High Accuracy in Predicting Recurrence Before Clinical Signs or Symptoms Emerge
SOUTH SAN FRANCISCO, Calif., Aug. 22, 2023 /PRNewswire/ — UroAmp, the noninvasive genomic urine test developed by Convergent Genomics, can detect bladder cancer or predict its recurrence before clinical signs or symptoms appear, according to a newly published study in the journal Clinical Cancer Research…
NEW STUDY SHOWS UROAMP CAN DETECT BLADDER CANCER NOT FOUND BY CYSTOSCOPY OR URINE CYTOLOGY
Noninvasive Genomic Urine Test Demonstrates High Accuracy in Predicting Recurrence Before Clinical Signs or Symptoms Emerge SOUTH SAN FRANCISCO, Calif., Aug. 22, 2023 /PRNewswire/ -- UroAmp, the noninvasive genomic urine test developed by Convergent Genomics, can...
Genomic Urine Test Detects Bladder Cancer from DNA Up to 12 Years Before Clinical Signs and Symptoms Appear
Advances in Next-Generation DNA Sequencing and Machine Learning Enable Rapid Analysis of Genetic Mutations to Determine Cancer Risk CHICAGO – May 1, 2023 – A new genomic urine test can help doctors accurately predict bladder cancer as many as 12 years before clinical...
New Studies on Convergent Genomics’ Urine Test for Bladder Cancer to be Presented at 2023 American Urological Association (AUA) Annual Meeting
CHICAGO, April 25, 2023 /PRNewswire/ -- Convergent Genomics announced UroAmp, the company's genomic urine test that uses next-generation DNA sequencing and machine learning to detect and monitor for bladder cancer, will be the subject of two new studies being...